HDAC9 and Thrombocytopenia: In prostate cancer, a phase I/II trial combining the HDAC inhibitor panobinostat with the anti-androgen bicalutamide in castration-resistant prostate cancer (CRPC) demonstrated improved outcomes if compared to historical controls, though high doses of panobinostat were associated with significant toxicity, mostly thrombocytopenia [36].